Pancreatic Cancer Research

ResearcherThe US Oncology NetworkActive in the last 2 years

Carlos Roberto Becerra

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-7735-8010; OpenAlex author ID A5108558388, A5110145965. Sources: ClinicalTrials.gov.

Their work

Papers
7
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers, 1 trial

Papers 7

  1. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  2. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  3. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Co-author DOI 10.1093/oncolo/oyae323↗
  4. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  5. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  6. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
  7. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative… Co-author DOI 10.1007/s10637-009-9307-8↗

Trials 1

  1. Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate Principal investigator NCT07344220↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Erkut Hasan Borazanci · 6 shared papers, 2019–2026 · strength 0.85
  2. Daniel D. Von Hoff · 6 shared papers, 2019–2026 · strength 0.85
  3. Derek Cridebring · 4 shared papers, 2022–2026 · strength 0.70
  4. Haiyong Han · 4 shared papers, 2022–2026 · strength 0.70
  5. Vincent M. Chung · 3 shared papers, 2025–2026 · strength 0.60
  6. John S. Bolton · 3 shared papers, 2022–2026 · strength 0.50
  7. Scott A. Celinski · 3 shared papers, 2022–2026 · strength 0.50
  8. Eunsung Jun · 3 shared papers, 2022–2026 · strength 0.50
  9. Joon Oh Park · 3 shared papers, 2022–2026 · strength 0.50
  10. Ajay Goel · 3 shared papers, 2022–2026 · strength 0.50
  11. Caiming Xu · 2 shared papers, 2026 · strength 0.39
  12. Mitsuro Kanda · 2 shared papers, 2026 · strength 0.39
  13. Laleh Golkar Melstrom · 2 shared papers, 2026 · strength 0.39
  14. Giulia Martina Cavestro · 2 shared papers, 2026 · strength 0.39
  15. Douglas B. Evans · 2 shared papers, 2026 · strength 0.39
  16. David L. Bartlett · 2 shared papers, 2026 · strength 0.39
  17. Alessandro Mannucci · 2 shared papers, 2026 · strength 0.39
  18. Song Cheol Kim · 2 shared papers, 2026 · strength 0.39
  19. Dong Shang · 2 shared papers, 2026 · strength 0.39
  20. Mustafa Raoof · 2 shared papers, 2026 · strength 0.39
  21. Ronald M. Evans · 3 shared papers, 2019–2025 · strength 0.35
  22. Gayle Jameson · 1 shared paper, 2025 · strength 0.20
  23. Anup Kasi · 1 shared paper, 2025 · strength 0.20
  24. Angela Tatiana Alistar · 1 shared paper, 2025 · strength 0.20
  25. Michael T. Barrett · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.